Immunophenotypes associated with bipolar disorder and lithium treatment.

Area of Science:

• Immunology
• Genetics
• Psychiatry

Background:

• Immune dysfunction is a potential factor in bipolar disorder etiology.
• The GADL1 gene's rs17026688 polymorphism is linked to lithium response in bipolar I disorder (BDI).
• The impact of GADL1 polymorphisms on BDI patient immunophenotypes remains unclear.

Purpose of the Study:

• To investigate immune profile differences in BDI patients based on GADL1 rs17026688 genotype.
• To explore the immunomodulatory effects of lithium on BDI patient immune cells.
• To determine if GADL1 polymorphisms affect immune cell subsets and lithium sensitivity.

Main Methods:

• Peripheral blood mononuclear cells (PBMCs) from BDI patients and healthy controls were analyzed.
• Immune cell populations were compared between individuals with and without the GADL1 rs17026688 T allele.
• In vitro lithium treatment was applied to BDI patient-derived PBMCs.

Main Results:

• BDI patients exhibited higher percentages of T cells, activated B cells, and monocytes compared to controls.
• Lithium treatment increased CD14+ monocytes and dendritic cells in BDI patient PBMCs.
• GADL1 T allele carriers with BDI showed distinct myeloid-derived suppressor cell levels and differential lithium sensitivity.

Conclusions:

• GADL1 rs17026688 polymorphisms are associated with immune dysregulation in BDI patients.
• Immune cell imbalances may contribute to BDI pathogenesis or progression.
• Lithium demonstrates immunomodulatory effects, potentially influenced by GADL1 genotype.